Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    BAY1093884

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03597022
Recruitment Status : Active, not recruiting
First Posted : July 24, 2018
Last Update Posted : September 25, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
The purpose of this study is to assess the safety and tolerability of multiple doses of a human monoclonal antibody (BAY1093884) given under the skin in subjects with hemophilia A or B. This antibody is intended to protect from bleeds by inhibiting a substance (Tissue Factor Pathway Inhibitor, TFPI) that reduces the ability of the body to form blood clots.

Condition or disease Intervention/treatment Phase
Hemophilia A and B Drug: BAY1093884 Phase 2

Detailed Description:
The primary objective of the study is to assess the safety and tolerability of multiple subcutaneous injections of BAY1093884 (anti-TFPI monoclonal antibody, immunoglobulin G2, IgG2) in patients with hemophilia A or B with or without inhibitors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
Actual Study Start Date : July 24, 2018
Estimated Primary Completion Date : October 15, 2019
Estimated Study Completion Date : October 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: Hemophilia patients_Arm 1
Patients receive a dose of 100 mg of BAY1093884.
Drug: BAY1093884
Patients will receive a subcutaneous injection of BAY1093884 once per week.
Other Name: Anti-TFPI (Tissue Factor Pathway Inhibitor) monoclonal antibody (immunoglobulin G2; IgG2)

Experimental: Hemophilia patients_Arm 2
Patients receive a dose of >100 mg and <400 mg of BAY1093884.
Drug: BAY1093884
Patients will receive a subcutaneous injection of BAY1093884 once per week.
Other Name: Anti-TFPI (Tissue Factor Pathway Inhibitor) monoclonal antibody (immunoglobulin G2; IgG2)

Experimental: Hemophilia patients_Arm 3
Patients receive a dose of BAY1093884 that is between the dose of Arm 2 and 400 mg.
Drug: BAY1093884
Patients will receive a subcutaneous injection of BAY1093884 once per week.
Other Name: Anti-TFPI (Tissue Factor Pathway Inhibitor) monoclonal antibody (immunoglobulin G2; IgG2)




Primary Outcome Measures :
  1. Frequency of drug-related adverse events (AEs) [ Time Frame: Up to 22 months ]
  2. Frequency of drug-related serious adverse events (SAEs) [ Time Frame: Up to 22 months ]
  3. Frequency of adverse events of special interest (AESIs) [ Time Frame: Up to 22 months ]
    Includes thromboembolic and thrombotic microangiopathic events and hypersensitivity reactions.

  4. Frequency of clinically relevant abnormalities in laboratory values [ Time Frame: Up to 22 months ]
    Includes various hematological and serum chemical parameters.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male severe hemophilic patients with undetectable FVIII activity <1% or FIX activity <2%, with or without inhibitors (any titer) are eligible.
  • Subjects with a past history of inhibitors (any inhibitor titer) are eligible.
  • Age ≥18 years.
  • Documentation of ≥4 bleeding episodes (any type or location of bleeds, treated or not) within the 6 months prior to screening.
  • For subjects on prophylaxis: Willingness to interrupt ongoing prophylaxis.
  • For subjects on immune tolerance induction (ITI): Willingness to interrupt ongoing ITI.

Exclusion Criteria:

  • History of any other coagulation disorder (particularly disseminated intravascular coagulopathy or combined FVIII/FV deficiency) or platelet disorder.
  • History of diseases related to venous thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis, thrombophlebitis) or thrombotic microangiopathy.
  • Risk factors for venous or arterial diseases (e.g., uncontrolled hypertension, uncontrolled diabetes).
  • History of cardiac, coronary and/or arterial peripheral atherosclerotic disease
  • Platelet count <100,000/μL.
  • Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of <200/mm3

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03597022


Locations
Layout table for location information
Australia, Western Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia, 6150
Austria
Allgemeines Krankenhaus der Stadt Wien
Wien, Austria, 1090
Bulgaria
Medical centre Hipokrat - N EOOD
Plovdiv, Bulgaria, 4000
SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD
Sofia, Bulgaria, 1756
MHAT Sveta Marina EAD
Varna, Bulgaria, 9010
France
Hôpital Louis Pradel - Bron
Bron, France, 69500
Hôpital Robert Debré - Reims Cedex
Reims Cedex, France, 51092
Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
Pecs, Hungary, 7624
Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano, Lombardia, Italy, 20122
Japan
Ogikubo Hospital
Suginami, Tokyo, Japan, 167-0035
Hiroshima University Hospital
Hiroshima, Japan, 734-8551
Korea, Republic of
Eulji University Hospital
Daejeon, Korea, Republic of, 302-799
New Zealand
Haematology Service, Canterbury Health Laboratories
Christchurch, New Zealand, 8011
Taiwan
Changhua Christian Hospital
Changhua, Taiwan, 500
Far Eastern Memorial Hospital
New Taipei City, Taiwan, 220
China Medical University Hospital
Taichung, Taiwan, 40447
National Taiwan University Hospital
Taipei, Taiwan, 10002
Taipei Medical University Hospital
Taipei, Taiwan, 110
United Kingdom
Kent & Canterbury Hospital
Canterbury, Kent, United Kingdom, CT1 3NG
University Hospital of Wales
Cardiff, United Kingdom, CF14 4XW
Royal Free Hospital
London, United Kingdom, NW3 2QG
Manchester Royal Infirmary
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Bayer

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03597022     History of Changes
Other Study ID Numbers: 19580
2017-003324-67 ( EudraCT Number )
First Posted: July 24, 2018    Key Record Dates
Last Update Posted: September 25, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Bayer:
Subcutaneous
Prophylaxis
Non-Inhibitors
Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Lipoprotein-associated coagulation inhibitor
Factor VIII
Coagulants
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Factor Xa Inhibitors
Antithrombins